Arbutus Biopharma Corporation (ABUS)

Name: Arbutus Biopharma Corporation Financial Statements
Creator: Quarter Results

Healthcare | Biotechnology

Latest reporting period: 2025-12-31

Latest Quarter

2025-12-31

Revenue

$1.1M

Net Income

-$3.8M

Operating Margin

1,371.3%

Free Cash Flow

-$39.6M

Debt / Assets

26.1%

Values are in USD and rounded to the nearest whole number unless noted.

Swipe horizontally to view all columns.

Income statement quarterly history for Arbutus Biopharma Corporation (ABUS).
Income Statement (Quarterly)	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Revenue	1,051,000	529,000	10,739,000	1,764,000
Cost of Revenue	11,000	11,000	0	8,959,000
Gross Profit	1,040,000	518,000	10,739,000	-7,195,000
Operating Expenses
R&D Expenses	0	0	0	0
SG&A Expenses	3,700,000	3,033,000	3,328,000	5,832,000
Operating Expenses	-4,754,000	8,811,000	9,251,000	27,463,000
Operating Income	14,412,000	-8,293,000	1,488,000	-34,658,000
Interest Expense	18,000	23,000	28,000	28,000
Income Before Tax	-3,756,000	-7,742,000	2,523,000	-24,526,000
Income Tax Expense	0	0	0	0
Net Income	-3,756,000	-7,742,000	2,523,000	-24,526,000
Per Share
EPS	-0.02	-0.04	0.01	-0.13
EPS Diluted	0.00	0.00	0.00	0.00

Income statement annual history for Arbutus Biopharma Corporation (ABUS).
Income Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue	14,083,000	6,171,000	18,141,000	39,019,000	10,988,000
Cost of Revenue	363,000	0	73,700,000	1,427,000	0
Gross Profit	13,720,000	6,171,000	-55,559,000	37,592,000	0
Operating Expenses
R&D Expenses	0	0	0	0	0
SG&A Expenses	15,893,000	22,108,000	22,475,000	17,834,000	17,136,000
Operating Expenses	40,771,000	82,490,000	96,244,000	102,242,000	82,638,000
Operating Income	-27,051,000	-76,319,000	-78,103,000	-65,456,000	-73,522,000
Interest Expense	97,000	137,000	459,000	1,726,000	2,857,000
Income Before Tax	-33,501,000	-69,920,000	-72,849,000	-65,012,000	-76,247,000
Income Tax Expense	0	0	0	4,444,000	0
Net Income	-33,501,000	-69,920,000	-72,849,000	-69,456,000	-76,247,000
Per Share
EPS	-0.17	-0.38	-0.44	-0.46	-0.83
EPS Diluted	0.00	0.00	0.00	0.00	0.00

Balance sheet quarterly history for Arbutus Biopharma Corporation (ABUS).
Balance Sheet (Quarterly)	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Assets
Cash and Cash Equivalents	36,330,000	26,285,000	30,776,000	109,282,000
Short Term Investments	86,293,000	99,718,000	116,137,000	46,035,000
Net Receivables	2,409,000	1,776,000	4,226,000	899,000
Inventory	0	0	-2,874,000	0
Total Current Assets	127,316,000	132,026,999	151,139,000	160,661,000
Property Plant Equipment	4,357,000	6,090,000	6,814,000	8,075,000
Goodwill and Intangibles	0	0	0	0
Total Assets	131,707,000	144,401,000	195,419,000	204,485,000
Liabilities
Account Payables	2,316,000	3,223,000	3,520,000	3,174,000
Short Term Debt	483,000	425,000	372,000	383,000
Total Current Liabilities	15,618,000	22,487,000	32,857,000	11,221,000
Long Term Debt	806,000	8,296,000	1,815,000	2,231,000
Total Liabilities	34,341,000	38,383,000	58,567,000	35,046,000
Shareholders Equity
Retained Earnings	-1,346,572,000	-1,276,652,000	-1,203,803,000	-1,134,347,000
Total Shareholders Equity	97,366,000	106,018,000	136,852,000	169,439,000

Balance sheet annual history for Arbutus Biopharma Corporation (ABUS).
Balance Sheet (Annual)	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31
Assets
Cash and Cash Equivalents	36,330,000	26,285,000	30,776,000	109,282,000	52,251,000
Short Term Investments	86,293,000	99,718,000	116,137,000	46,035,000	71,017,000
Net Receivables	2,409,000	1,776,000	4,226,000	899,000	1,312,000
Inventory	0	0	-2,874,000	0	0
Total Current Assets	127,316,000	132,026,999	151,139,000	160,661,000	127,704,000
Property Plant Equipment	4,357,000	6,090,000	6,814,000	8,075,000	9,332,000
Goodwill and Intangibles	0	0	0	0	0
Total Assets	131,707,000	144,401,000	195,419,000	204,485,000	137,080,000
Liabilities
Account Payables	2,316,000	3,223,000	3,520,000	3,174,000	2,994,000
Short Term Debt	483,000	425,000	372,000	383,000	390,000
Total Current Liabilities	15,618,000	22,487,000	32,857,000	11,221,000	9,541,000
Long Term Debt	806,000	8,296,000	1,815,000	2,231,000	2,593,000
Total Liabilities	34,341,000	38,383,000	58,567,000	35,046,000	35,114,000
Shareholders Equity
Retained Earnings	-1,346,572,000	-1,276,652,000	-1,203,803,000	-1,134,347,000	-1,045,961,000
Total Shareholders Equity	97,366,000	106,018,000	136,852,000	169,439,000	101,966,000

Cash flow quarterly history for Arbutus Biopharma Corporation (ABUS).
Cash Flow Statement (Quarterly)	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Operating Activities
Net Income	-33,501,000	-69,920,000	-72,849,000	-69,456,000
Depreciation & Amortization	363,000	1,380,000	1,404,000	1,427,000
Stock Based Compensation	6,953,000	8,986,000	9,301,000	7,182,000
Change in Working Capital	-10,023,000	-2,829,000	-18,233,000	29,243,000
Operating Cash Flow	-39,637,000	-64,850,000	-85,936,000	-35,356,000
Investing Activities
Capital Expenditure	0	-182,000	-1,008,000	-512,000
Investments	0	-182,000	-1,008,000	-512,000
Investing Cash Flow	15,580,000	22,948,000	50,773,000	-74,942,000
Financing Activities
Debt Repayment	0	0	0	0
Common Stock Issued/Repurchased	5,721,000	44,123,000	30,647,000	42,270,000
Dividends Paid	0	0	0	0
Financing Cash Flow	5,721,000	51,996,000	30,647,000	31,814,000
Summary
Free Cash Flow	-39,637,000	-65,032,000	-86,944,000	-35,868,000
Net Change in Cash	-18,322,000	10,045,000	-4,491,000	-78,506,000

Cash flow annual history for Arbutus Biopharma Corporation (ABUS).
Cash Flow Statement (Annual)	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Operating Activities
Net Income	-33,501,000	-69,920,000	-72,849,000	-69,456,000	-76,247,000
Depreciation & Amortization	363,000	1,380,000	1,404,000	1,427,000	1,753,000
Stock Based Compensation	6,953,000	8,986,000	9,301,000	7,182,000	6,424,000
Change in Working Capital	-10,023,000	-2,829,000	-18,233,000	29,243,000	930,000
Operating Cash Flow	-39,637,000	-64,850,000	-85,936,000	-35,356,000	-67,532,000
Investing Activities
Capital Expenditure	0	-182,000	-1,008,000	-512,000	-809,000
Investments	0	-182,000	-1,008,000	-512,000	-809,000
Investing Cash Flow	15,580,000	22,948,000	50,773,000	-74,942,000	-12,678,000
Financing Activities
Debt Repayment	0	0	0	0	0
Common Stock Issued/Repurchased	5,721,000	44,123,000	30,647,000	42,270,000	134,665,000
Dividends Paid	0	0	0	0	0
Financing Cash Flow	5,721,000	51,996,000	30,647,000	31,814,000	137,236,000
Summary
Free Cash Flow	-39,637,000	-65,032,000	-86,944,000	-35,868,000	-68,341,000
Net Change in Cash	-18,322,000	10,045,000	-4,491,000	-78,506,000	57,031,000